Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Huub J. Kleijn"'
Autor:
Neeraj Gupta, Karen L. Reckamp, David R. Camidge, Huub J. Kleijn, Aziz Ouerdani, Francesco Bellanti, John Maringwa, Michael J. Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 5, Pp 1143-1154 (2022)
Abstract The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC). A population pharmacoki
Externí odkaz:
https://doaj.org/article/c85cc577cdaa4f20a4aec707f1e3905c
Autor:
Yulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, Paul M. Diderichsen, Huub J. Kleijn, Kosalaram Goteti, Andreas Schroeder, Karthik Venkatakrishnan
Publikováno v:
Cancer Research. 82:5424-5424
Xevinapant, an antagonist of Inhibitor of Apoptosis Proteins (IAPs) showed significant improvement in locoregional control at 18 months (LRC18; primary endpoint), overall survival (OS) and progression-free survival (PFS) at an oral dose of 200 mg/day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823aab57fc098389b7e5bcb232669b81
https://doi.org/10.1158/1538-7445.am2022-5424
https://doi.org/10.1158/1538-7445.am2022-5424
Autor:
Marieke L. de Kam, Paul C C M Passier, Adam F Cohen, Lineke Zuurman, Joop M A van Gerven, Huub J Kleijn
Publikováno v:
Journal of Psychopharmacology. 24:1689-1696
An ideal drug for outpatient treatments under conscious sedation would have both sedative and analgesic properties. CB1/CB2 agonists are expected to have sedative, amnestic, analgesic and anti-emetic properties. The main objective of this first study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6baa62ae5e6c48616bd884c7393c6c1
https://doi.org/10.1177/0269881109106913
https://doi.org/10.1177/0269881109106913
Publikováno v:
British journal of clinical pharmacology. 72(3)
An integrated population pharmacokinetic-pharmacodynamic model was developed with the following aims: to simultaneously describe pharmacokinetic behaviour of sugammadex and rocuronium; to establish the pharmacokinetic-pharmacodynamic model for rocuro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fa7980d19f91cba73b117ae116113cc3
https://pubmed.ncbi.nlm.nih.gov/21535448
https://pubmed.ncbi.nlm.nih.gov/21535448